A private equity firm founded in the USA invests in companies with high growth potential. The firm also considers in-licensing of technologies and strategic acquisitions. For equity investments, the firm prefers that companies are located in the Eastern US and Midwest, but for acquisitions and in-licensing, the firm will consider companies located around the globe. The firm also has an early-stage focused fund through which the firm makes angel investments into high potential, early-stage companies. With this fund, the firm typically invests up to $250K in preferred equity.

The firm primarily focuses on the following sectors: Diagnostics (including digital), Pharma Services/Outsourcing, Digital Health, and Medical Devices. The firm has a strong preference for companies working with platform technologies. For equity investments, the firm looks for companies that have reached commercialization. With regards to their early-stage fund, the firm primarily seeks companies in healthcare services and SaaS outsourcing businesses.

The firm is looking for experienced management teams with domain expertise and leadership skills that are capable of taking the company to the next value inflection point or additional capital raise. The firm is interested in company that are profitable or near breakeven and have demonstrated substantial opportunity for growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm with offices in China is managing two funds in RMB with a total of over 300M RMB, and is planning to raise a USD fund in the near future.

The firm is currently focusing on early-stage (from angel to series A) investments, each investment ranging from 5MM RMB (~0.7MM) to 20MM RMB (~3MM).

With the support of a synergistic incubator business and its accelerating program, as well as a dynamic innovation ecosystem built upon these business arms, the firm has a broad reach of disruptive technologies and is progressively investing in the field of life science to support the business strategy and organic growth of their parent company.

The firm is mainly looking at fields of next generation of molecule diagnostics, microfluidics, synthetic biology, omics technology, bioinformatics, genetic testing, gene therapy and immunotherapy, microbiome, etc. The firm is open to investing in the field of life science and precision medicine, focusing on the frontier research and technologies in DNA, RNA, protein, cell, tissue and other integrative omics. Therapeutics, especially gene therapy, oncology therapy, and eye disease therapy; diagnostics sector, especially in gene detection, molecular diagnostics, CNS and IVD; also some medical devices. However, the firm has less interest in technologies that are already in the field of very fierce competition, with big players already in.

The firm prefers companies with a China angle, especially companies who are willing to register an entity in China. They mostly are interested in companies with novel and original technologies and a clear direction of clinical applications.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A  corporate venture capital arm of a global pharmaceutical with headquarters in Western Europe can invest up to $5m to a round. They will participate in rounds for digital health companies at all stages, as early as seed and through later venture rounds. They are open to working with companies globally.

Within digital health, the firm is seeking companies that are in the prevention and adherence space as well as digital medical devices and big data analytics platforms that address chronic diseases (Diabetes, Obesity and Cardiovascular), respiratory diseases, oncology, consumer and mental health. Past investments in the space include a wearable nicotine delivery device with integrated software and data analytics component to aid in smoking cessation.

The firm prefers to work with management teams with a track record in the space and a strong business plan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Western Europe owns several funds and currently focuses on investments in Europe based diagnostics companies. The firm invests in Europe and North America, and typically allocates about €5 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics and diagnostics to treat rare diseases.  The firm is agnostic regarding technologies and indication areas, and typically invests early but is open to companies with assets ranging from preclinical development through Phase II.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm that represents a high net worth family office has offices in Western Europe. The firm makes equity investments in life science companies, typically at the Series B stage or later; the firm allocates a total of EUR 3-10 million over the life of an investment. The firm invests in Europe and the US.

In the life science sector, the firm invests in medical applications (therapeutics, diagnostics, and medical devices), life science services and tools, and agtech / food tech. For therapeutics companies, the firm only invests in companies with assets that have obtained data from in-human clinical trials (at minimum, human safety data is required). For medtech or diagnostic companies, the product must be no more than 1 year from commercialization. The firm invests broadly in the life science field, but has a specific interest in technologies at the intersection between the healthcare and food industries, including nutraceuticals and the microbiome.

The firm is a hands-on investor that prefers to take a board seat and work closely with management, and therefore prefers to invest in companies located close to their offices. The firm prefers to invest as part of a strong syndicate that includes experienced investors with whom the firm has pre-existing connections.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family investment group based in the USA is looking to invest in technologies related to ophthalmology and oncology that are in the pre-clinical to Ph I stages. The firm will invest in seed and series A rounds up to $10M. The firm is willing to invest globally, with a special interest in companies based in North America, Europe and China.

The firm is interested in therapeutics, medical device and diagnostics companies with technologies in the ophthalmology and oncology spaces. The firm may consider digital health companies as well. For ophthalmology-related companies, Halcyon is most interested in small molecules or combination devices. For oncology-related companies, the firm prefers I/O technologies or diagnostics.

The firm prefers to take a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital arm of a large Asian financial conglomerate mainly invests in the IT, communications, cultural/creative, alternative energies, biotechnology, and medical/healthcare sectors. The firm seeks to invest in commercial stage or expansion phase companies that are 3-5 years from IPO. Typical equity allocations range from US$1-3 million and can be up to US$5 million. The firm is now focused on China and South East Asia, with interest in opportunities from North America and Europe to a lesser extent.

Within healthcare, the firm is interested in all sectors of medical technology, including consumer and non-consumer products. The firm is agnostic to indications. The firm is less interested in therapeutics, but it would consider drug reformulation. The firm looks for products that are ready for commercialization or at the commercial stage and seeking growth/expansion capital.

The firm looks for a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.